The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice
Open accessAbstract
Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of antidiabetic compounds, are effective in the treatment of hyperglycemia. Because atherosclerosis-related cardiovascular diseases are the major complications of diabetes, it is important to determine the effect of DPP-4 inhibitors on atherosclerosis. In this study, nondiabetic and diabetic apolipoprotein E-deficient mice were treated with DPP-4 inhibitor alogliptin for 24 weeks, and atherosclerotic lesions in aortic origins were examined. Results showed that diabetes significantly increased atherosclerotic lesions, but alogliptin treatment reduced atherosclerotic lesions in diabetic mice. Metabolic studies showed that diabetes increased plasma glucose and that alogliptin treatment reduced glucose. Furthermore, immunohistochemistry study showed that diabetes increased interleukin-6 (IL-6) and IL-1β protein expression in atherosclerotic plaques, but alogliptin treatment attenuated diabetes-augmented IL-6 and IL-1β expression. In consistence with the observations from the mouse models, our in vitro studies showed that alogliptin-inhibited toll-like receptor 4 (TLR-4)-mediated upregulation of IL-6, IL-1β, and other proinflammatory cytokines by mononuclear cells. Taken together, our findings showed that alogliptin-inhibited atherosclerosis in diabetic apolipoprotein E-deficient mice and that the actions of alogliptin on both glucose and inflammation may contribute to the inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasu, M. R., Devaraj, S., Park, S., & Jialal, I. (2010) · Diabetes Care · doi:10.2337/dc09-1799 · Cited by 572
Feng, J., Zhang, Z., Wallace, M. B., Stafford, J. A., Kaldor, S. W., Kassel, D. B., Navre, M., Shi, L., Skene, R. J., Asakawa, T., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070104l · Cited by 409
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S. M., Wakino, S., Noh, G. J., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 389
CD26: a surface protease involved in T-cell activation
Fleischer, B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90316-6 · Cited by 329
Lehr, H., Mankoff, D. A., Corwin, D., Santeusanio, G., & Gown, A. M. (1997) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549704501112 · Cited by 308
DeFronzo, R. A., Fleck, P. R., Wilson, C., Mekki, Q. A., & on behalf of the Alogliptin Study 010 Group (2008) · Diabetes Care · doi:10.2337/dc08-1035 · Cited by 227
TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis
Michelsen, K. S., Doherty, T. M., Shah, P. K., & Arditi, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.5901 · Cited by 211
Ferreira, L., Teixeira‐Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R. M. A., Garrido, P., Sereno, J., Fernandes, R., et al. (2010) · Mediators of Inflammation · doi:10.1155/2010/592760 · Cited by 196
Ulrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 174
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice
Lin, R.-Y., Choudhury, R. P., Cai, W., Lu, M. M., Fallon, J. T., Fisher, E. A. A., & Vlassara, H. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00050-9 · Cited by 169
Research works printed but not linked: 1
- Jungraithmayr, 31, Peptides, 585-, 591
Cited by
Sorted by citations
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 255
Zhong, J., Rao, X., & Rajagopalan, S. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.012 · Cited by 209
Waumans, Y., Baerts, L., Kehoe, K., Lambeir, A., & Meester, I. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00387 · Cited by 194
DPP4 in Cardiometabolic Disease
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 190
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Metadata
- Authors
- Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F., & Huang, Y.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Huang, Yan
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2011-08
- Volume
- 58
- Issue
- 2
- Pages
- 157-166
- ISSN
- 0160-2446 (ISSN-L)
- PMC
- PMC3155015
- OpenAlex
- W2059903872
- Cited by
- 156
- References
- 42
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 6 · 2018: 13 · 2017: 10 · 2016: 16 · 2015: 22 · 2014: 17 · 2013: 23 · 2012: 13
- FWCI
- 13.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Cardiovascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Dental and Craniofacial Research (R01DE016353, DE016353)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- alogliptin, DPP-4 inhibitors, atherosclerosis, diabetes mellitus, ApoE-deficient mice, interleukin-6, IL-1β, TLR4, inflammation, glucose, mononuclear cells, aortic atherosclerotic lesions
- MeSH terms
- Interleukin-6 Inhibitors, Animals, Apolipoproteins E, Blood Glucose, Cholesterol, Diabetes Mellitus, Experimental, Enzyme-Linked Immunosorbent Assay, Humans, Male, Piperidines, Triglycerides, Uracil, Mice, Knockout, Dipeptidyl Peptidase 4, U937 Cells, Atherosclerosis, Mice, Interleukin-1beta, Dipeptidyl-Peptidase IV Inhibitors, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
